ArticleMolecular diversity2026
De novo synthesis of tryptanthrin and its derivatives from indole: engineering a sustainable photocatalytic strategy.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Design, Synthesis, Molecular Dynamics, and In Vitro Evaluation of Isatin-Based Quinazoline Derivatives as Potential Antidiabetic Agents.Chemistry & biodiversity · 2026Article
- Chemistry and Biological Activity of 11Molecules (Basel, Switzerland) · 2026Review
- Alkaloids as Emerging Neuroprotective Agents for Neurodegenerative Disorders: Insights into Tryptanthrin and Its Derivatives.International journal of molecular sciences · 2026Review
- Tryptophanase Mining and Characterization toward the Biological Production of Indole Derivatives.ACS omega · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Tryptanthrin is a natural alkaloidal molecule [IUPAC name 6,12-dihydro-6,12-dioxoindolo-(2,1-b)-quinazoline], possessing an indoloquinazoline moiety. Since first being discovered in 1979, it and its analogs generated great interest in the fields of medicinal chemistry, life science, and materials science. Protocols for synthesizing tryptanthrins with the features of facile, eco-friendly, and mild reaction conditions remain an underdeveloped area. This new protocol, leveraging Rose Bengal as a photo-catalyst and commercially available substituted indoles as starting materials, enables selective synthesis under mild reaction conditions, expanding the substrate scope, complementing existing methods, and investigating the possible reaction mechanism. This approach emphasizes eco-friendliness, cost-effectiveness, and scalability, making it suitable for diverse applications. This innovation holds promise for synthesizing tryptanthrin-based bioactive compounds and materials relevant to chemistry and beyond.
Indexed as
Identifiers
40407999What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.